Search results for "pharmaceutical company"

HK Innoen's 'K-Cab' Applies for New Drug Approval from the U.S. FDA

HK Innoen's 'K-Cab' Applies for New Drug Approval from the U.S. FDA

HK Innoen announced on the 13th that its U.S. partner, Sevela Pharmaceuticals, a subsidiary and specialist in gastrointestinal medicines, submitted a...
Oral Obesity Drug Launched in the U.S.… Where is K-Bio Pharmaceutical Now?

Oral Obesity Drug Launched in the U.S.… Where is K-Bio Pharmaceutical Now?

Denmark's Novo Nordisk's obesity drug ‘Wegovy Pill (ingredient name Semaglutide)’ has recently been launched in the U. S.
Ligakem Bio Receives ADC Platform Technology Fees from Ono Pharmaceutical

Ligakem Bio Receives ADC Platform Technology Fees from Ono Pharmaceutical

Ligakem Bioscience announced on the 8th that it is set to receive milestone payments related to the development...
Next-Generation Precision Medicine for Cancer Treatment... Amgen Acquires UK Biotech for 1 Trillion Won

Next-Generation Precision Medicine for Cancer Treatment... Amgen Acquires UK Biotech for 1 Trillion Won

Global pharmaceutical company Amgen is acquiring a UK biotech for up to $840 million (approximately 1.
Bluebird, Phoenix, and... Who Will Be ABL Bio's Next Technology Export Partner?

Bluebird, Phoenix, and... Who Will Be ABL Bio's Next Technology Export Partner?

After Bluebird and Phoenix, what kind of bird will be the next partner for ABL Bio? ABL Bio is scheduled to meet with...
Dr. Han Jin-hwan, Formerly of Merck (MSD), Appointed Head of New Drug Research Institute at Ligand Pharmaceuticals

Dr. Han Jin-hwan, Formerly of Merck (MSD), Appointed Head of New Drug Research Institute at Ligand Pharmaceuticals

Ligand Pharmaceuticals announced on the 5th that it has recruited Dr. Han Jin-hwan, formerly of Merck, as the head of...
Samsung Bioepis to Directly Sell Ophthalmic Drug Baivubiz in Europe

Samsung Bioepis to Directly Sell Ophthalmic Drug Baivubiz in Europe

Samsung Bioepis announced on the 4th that it has recovered the European commercialization rights for the ophthalmic...